Product Highlight - Abilify Maintena

The 1^st and only FDA approved once-monthly* LAI for the maintenance treatment of Bipolar I Disorder in adult¹
• Reduced the risk of any mood episode recurrence by nearly 50% in a 52–week study^2,3
• Significantly delayed time to recurrence for a manic episode and mixed episode^2,3
• 73% of the patients remained recurrence-free vs 49% on placebo^2,3
• Lower risks of discontinuation compared with patients received oral antipsychotic treatment⁴

*Establish tolerability with oral aripiprazole before initiating therapy. Along with the first injection, patients should take oral aripiprazole or current antipsychotics for 14 consecutive days.⁵
LAI = long-acting injectable.

References:
1. Otsuka Pharmaceutical Co., Ltd. (2017) Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder [Press release]. 29 July. Available at: https://www.otsuka.co.jp/en/company/newsreleases/2017/20170729_1.html (Accessed: 13 February 2019).
2. Calabrese JR, et al. J Clin Psychiatry. 2017;78(3):324-331.
3. Data on file. ABIMAI-178.
4. Yan T et al. Adv Ther. 2018;35:1612 – 1625.
5. Abilify Maintena package insert.